TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Community Trial of Newborn Vitamin A Supplementation to Reduce Infant Mortality in Rural Bangladesh
Brief Summary: The purpose of this trial is determine whether a 50,000 IU oral dose of vitamin A delivered to newborn infants within the first days of life, reduces six-month infant mortality by at least 15%. The trial will also evaluate whether the survival impact of newborn vitamin A dosing is modified by concurrent weekly, routine maternal vitamin A or beta-carotene supplementation during pregnancy through three months postpartum, gestational age and birth size.


Options:
A: Arm Label: Vitamin A; Type: EXPERIMENTAL; Interventions: Dietary Supplement: retinyl palmitate | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: retinyl palmitate; Assigned to Arm(s): Vitamin A | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): Placebo
B: N/A
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: vitamin A supplementation (15,000 ug retinol equivalents or 50,000 IU) | Arm Label: Vitamin A; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: vitamin A supplementation (15,000 ug retinol equivalents or 50,000 IU) | Intervention Type: DIETARY_SUPPLEMENT; Name: vitamin A supplementation (15,000 ug retinol equivalents or 50,000 IU); Assigned to Arm(s): Placebo, Vitamin A
D: Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: vitamin A supplement; Type: ACTIVE_COMPARATOR; Interventions: Drug: vitamin A supplements | Intervention Type: DRUG; Name: vitamin A supplements; Assigned to Arm(s): vitamin A supplement | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Community Trial of Newborn Vitamin A Supplementation to Reduce Infant Mortality in Rural Bangladesh
Brief Summary: The purpose of this trial is determine whether a 50,000 IU oral dose of vitamin A delivered to newborn infants within the first days of life, reduces six-month infant mortality by at least 15%. The trial will also evaluate whether the survival impact of newborn vitamin A dosing is modified by concurrent weekly, routine maternal vitamin A or beta-carotene supplementation during pregnancy through three months postpartum, gestational age and birth size.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: vitamin A supplementation (15,000 ug retinol equivalents or 50,000 IU) | Arm Label: Vitamin A; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: vitamin A supplementation (15,000 ug retinol equivalents or 50,000 IU) | Intervention Type: DIETARY_SUPPLEMENT; Name: vitamin A supplementation (15,000 ug retinol equivalents or 50,000 IU); Assigned to Arm(s): Placebo, Vitamin A
B: Arm Label: Vitamin A; Type: EXPERIMENTAL; Interventions: Dietary Supplement: retinyl palmitate | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: retinyl palmitate; Assigned to Arm(s): Vitamin A | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Vitamin A | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin A; Assigned to Arm(s): 1 | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): 2
D: Arm Label: Vitamin A; Type: EXPERIMENTAL; Interventions: Drug: Vitamin A | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Vitamin A | Intervention Type: DRUG; Name: Vitamin A; Assigned to Arm(s): Placebo, Vitamin A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Community Trial of Newborn Vitamin A Supplementation to Reduce Infant Mortality in Rural Bangladesh
Brief Summary: The purpose of this trial is determine whether a 50,000 IU oral dose of vitamin A delivered to newborn infants within the first days of life, reduces six-month infant mortality by at least 15%. The trial will also evaluate whether the survival impact of newborn vitamin A dosing is modified by concurrent weekly, routine maternal vitamin A or beta-carotene supplementation during pregnancy through three months postpartum, gestational age and birth size.


Options:
A: Arm Label: Boys 1; Type: ACTIVE_COMPARATOR; Interventions: Biological: OPV | Arm Label: Boys 2; Type: EXPERIMENTAL; Interventions: Biological: OPV plus BCG | Arm Label: Girls 1; Type: ACTIVE_COMPARATOR; Interventions: Biological: OPV | Arm Label: Girls 2; Type: EXPERIMENTAL; Interventions: Biological: OPV plus BCG | Intervention Type: BIOLOGICAL; Name: OPV; Assigned to Arm(s): Boys 1 | Intervention Type: BIOLOGICAL; Name: OPV plus BCG; Assigned to Arm(s): Boys 2 | Intervention Type: BIOLOGICAL; Name: OPV; Assigned to Arm(s): Girls 1 | Intervention Type: BIOLOGICAL; Name: OPV plus BCG; Assigned to Arm(s): Girls 2
B: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Peer-support for exclusive breastfeeding | Arm Label: No intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Peer-support for exclusive breastfeeding; Assigned to Arm(s): Intervention
C: Intervention Type: DRUG; Name: Vitamin A; Assigned to Arm(s): N/A
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: vitamin A supplementation (15,000 ug retinol equivalents or 50,000 IU) | Arm Label: Vitamin A; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: vitamin A supplementation (15,000 ug retinol equivalents or 50,000 IU) | Intervention Type: DIETARY_SUPPLEMENT; Name: vitamin A supplementation (15,000 ug retinol equivalents or 50,000 IU); Assigned to Arm(s): Placebo, Vitamin A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Cancer Prevention Mastery Model Internet Intervention
Brief Summary: RATIONALE: An internet-based health behavior program that provides information about physical activity, fitness, and nutrition may help participants become healthier and reduce the risk of developing cancer.

PURPOSE: This randomized clinical trial is studying an individualized internet-based health behavior program to see how well it works compared to a standard internet-based health behavior program in preventing cancer and improving physical activity, fitness, and nutrition in participants who are physically inactive with a higher body mass index.


Options:
A: Arm Label: Lifestyle intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Lifestyle Intervention | Arm Label: control; Type: EXPERIMENTAL; Interventions: Other: control group | Intervention Type: BEHAVIORAL; Name: Lifestyle Intervention; Assigned to Arm(s): Lifestyle intervention | Intervention Type: OTHER; Name: control group; Assigned to Arm(s): control
B: Intervention Type: BEHAVIORAL; Name: behavioral dietary intervention; Assigned to Arm(s): N/A | Intervention Type: OTHER; Name: educational intervention; Assigned to Arm(s): N/A | Intervention Type: OTHER; Name: internet-based intervention; Assigned to Arm(s): N/A | Intervention Type: OTHER; Name: preventative dietary intervention; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: evaluation of cancer risk factors; Assigned to Arm(s): N/A
C: Intervention Type: BEHAVIORAL; Name: Internet weight loss with SlimFast and human counseling; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Internet weight loss with SlimFast and computer counseling; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Internet weight loss program with SlimFast; Assigned to Arm(s): N/A
D: Arm Label: Face-to-face counseling; Type: EXPERIMENTAL; Interventions: Behavioral: Face-to-face counseling | Arm Label: Telephone Counseling; Type: EXPERIMENTAL; Interventions: Behavioral: Telephone counseling | Arm Label: Mail contact; Type: ACTIVE_COMPARATOR; Interventions: Other: Mail contact | Intervention Type: BEHAVIORAL; Name: Face-to-face counseling; Assigned to Arm(s): Face-to-face counseling | Intervention Type: BEHAVIORAL; Name: Telephone counseling; Assigned to Arm(s): Telephone Counseling | Intervention Type: OTHER; Name: Mail contact; Assigned to Arm(s): Mail contact

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Double-Blind, Controlled, Randomized, Phase III Study of the Efficacy of an HPV16/18 VLP Vaccine in the Prevention of Advanced Cervical Intraepithelial Neoplasia (CIN2, CIN3, Adenocarcinoma In Situ [AIS] and Invasive Cervical Cancer) Associated With HPV 16 or HPV 18 Cervical Infection in Healthy Young Adult Women in Costa Rica.
Brief Summary: RATIONALE: Chemoprevention is the use of certain drugs to keep cancer form forming, growing, or coming back. Vaccines may help the body build an effective immune response against human papillomavirus and may be effective in preventing cervical intraepithelial neoplasia or cervical cancer. It is not yet known whether human papillomavirus vaccine is more effective than hepatitis A vaccine in preventing cervical intraepithelial neoplasia or cervical cancer.

PURPOSE: This randomized phase III trial is studying human papillomavirus vaccine to see how well it works compared to hepatitis A vaccine in preventing cervical intraepithelial neoplasia or cervical cancer in younger healthy participants.


Options:
A: Arm Label: Cervarix 1 Group; Type: EXPERIMENTAL; Interventions: Biological: GSK Biologicals' HPV vaccine 580299 | Arm Label: Cervarix 2 Group; Type: ACTIVE_COMPARATOR; Interventions: Biological: GSK Biologicals' HPV vaccine 580299 | Arm Label: Cervarix 3 Group; Type: EXPERIMENTAL; Interventions: Biological: GSK Biologicals' HPV vaccine 580299 | Intervention Type: BIOLOGICAL; Name: GSK Biologicals' HPV vaccine 580299; Assigned to Arm(s): Cervarix 1 Group, Cervarix 2 Group, Cervarix 3 Group
B: Arm Label: Cervarix Group; Type: EXPERIMENTAL; Interventions: Biological: Cervarix vaccine | Arm Label: Engerix-B Group; Type: ACTIVE_COMPARATOR; Interventions: Biological: Engerix-B vaccine | Intervention Type: BIOLOGICAL; Name: Cervarix vaccine; Assigned to Arm(s): Cervarix Group | Intervention Type: BIOLOGICAL; Name: Engerix-B vaccine; Assigned to Arm(s): Engerix-B Group
C: Arm Label: Cohort A (Trial Cohort, Vaccinated during HPV-008); Type: N/A; Interventions: Procedure: Screening for cervical cancer | Arm Label: Cohort B1 + B2; Type: N/A; Interventions: Procedure: Screening for cervical cancer | Arm Label: Cohort C (Referent Cohort, Non-Vaccinated); Type: N/A; Interventions: Procedure: Screening for cervical cancer | Intervention Type: PROCEDURE; Name: Screening for cervical cancer; Assigned to Arm(s): Cohort A (Trial Cohort, Vaccinated during HPV-008), Cohort B1 + B2, Cohort C (Referent Cohort, Non-Vaccinated)
D: Arm Label: Cervarix Group; Type: EXPERIMENTAL; Interventions: Biological: human papillomavirus 16/18 L1 virus-like particle/AS04 vaccine | Arm Label: Havrix Group; Type: ACTIVE_COMPARATOR; Interventions: Biological: hepatitis A inactivated virus vaccine | Intervention Type: BIOLOGICAL; Name: human papillomavirus 16/18 L1 virus-like particle/AS04 vaccine; Assigned to Arm(s): Cervarix Group | Intervention Type: BIOLOGICAL; Name: hepatitis A inactivated virus vaccine; Assigned to Arm(s): Havrix Group

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Double-Blind, Controlled, Randomized, Phase III Study of the Efficacy of an HPV16/18 VLP Vaccine in the Prevention of Advanced Cervical Intraepithelial Neoplasia (CIN2, CIN3, Adenocarcinoma In Situ [AIS] and Invasive Cervical Cancer) Associated With HPV 16 or HPV 18 Cervical Infection in Healthy Young Adult Women in Costa Rica.
Brief Summary: RATIONALE: Chemoprevention is the use of certain drugs to keep cancer form forming, growing, or coming back. Vaccines may help the body build an effective immune response against human papillomavirus and may be effective in preventing cervical intraepithelial neoplasia or cervical cancer. It is not yet known whether human papillomavirus vaccine is more effective than hepatitis A vaccine in preventing cervical intraepithelial neoplasia or cervical cancer.

PURPOSE: This randomized phase III trial is studying human papillomavirus vaccine to see how well it works compared to hepatitis A vaccine in preventing cervical intraepithelial neoplasia or cervical cancer in younger healthy participants.


Options:
A: Arm Label: Cervarix Group; Type: EXPERIMENTAL; Interventions: Biological: human papillomavirus 16/18 L1 virus-like particle/AS04 vaccine | Arm Label: Havrix Group; Type: ACTIVE_COMPARATOR; Interventions: Biological: hepatitis A inactivated virus vaccine | Intervention Type: BIOLOGICAL; Name: human papillomavirus 16/18 L1 virus-like particle/AS04 vaccine; Assigned to Arm(s): Cervarix Group | Intervention Type: BIOLOGICAL; Name: hepatitis A inactivated virus vaccine; Assigned to Arm(s): Havrix Group
B: Arm Label: qHPV Vaccine in Base Study; Type: EXPERIMENTAL; Interventions: Biological: V501 | Arm Label: Placebo in Base Study; Type: PLACEBO_COMPARATOR; Interventions: Biological: Comparator: Placebo | Arm Label: qHPV Vaccine in Extension Study; Type: EXPERIMENTAL; Interventions: Biological: V501 | Intervention Type: BIOLOGICAL; Name: V501; Assigned to Arm(s): qHPV Vaccine in Base Study, qHPV Vaccine in Extension Study | Intervention Type: BIOLOGICAL; Name: Comparator: Placebo; Assigned to Arm(s): Placebo in Base Study
C: Arm Label: Cervarix Group; Type: EXPERIMENTAL; Interventions: Biological: GSK Biologicals' HPV-16/18 Vaccine (Cervarix™) | Arm Label: Havrix Group; Type: ACTIVE_COMPARATOR; Interventions: Biological: Havrix™ | Intervention Type: BIOLOGICAL; Name: GSK Biologicals' HPV-16/18 Vaccine (Cervarix™); Assigned to Arm(s): Cervarix Group | Intervention Type: BIOLOGICAL; Name: Havrix™; Assigned to Arm(s): Havrix Group
D: Arm Label: Cervarix Group; Type: EXPERIMENTAL; Interventions: Biological: Cervarix vaccine | Arm Label: Engerix-B Group; Type: ACTIVE_COMPARATOR; Interventions: Biological: Engerix-B vaccine | Intervention Type: BIOLOGICAL; Name: Cervarix vaccine; Assigned to Arm(s): Cervarix Group | Intervention Type: BIOLOGICAL; Name: Engerix-B vaccine; Assigned to Arm(s): Engerix-B Group

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Improving Coronary Prevention in a County Health System
Brief Summary: To examine whether the Stanford Health Education and Risk Reduction Training (HEAR2T) program , a case management approach, can be effectively used to manage the risk of coronary artery disease.


Options:
A: Arm Label: Active Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Financial Incentive Group I; Type: EXPERIMENTAL; Interventions: Behavioral: Financial Incentive Group I | Arm Label: Financial Incentives Group II; Type: EXPERIMENTAL; Interventions: Behavioral: Financial Incentive Group II | Intervention Type: BEHAVIORAL; Name: Financial Incentive Group I; Assigned to Arm(s): Financial Incentive Group I | Intervention Type: BEHAVIORAL; Name: Financial Incentive Group II; Assigned to Arm(s): Financial Incentives Group II
B: Arm Label: Routine general practice care; Type: NO_INTERVENTION; Interventions: Behavioral: Structured personal care | Intervention Type: BEHAVIORAL; Name: Structured personal care; Assigned to Arm(s): Routine general practice care
C: Arm Label: Care Coordination; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Care Coordination | Arm Label: Home Telemedicine; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Home Telemedicine | Intervention Type: BEHAVIORAL; Name: Care Coordination; Assigned to Arm(s): Care Coordination | Intervention Type: BEHAVIORAL; Name: Home Telemedicine; Assigned to Arm(s): Home Telemedicine
D: Arm Label: Immediate Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: risk reduction | Arm Label: Delayed Intervention; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: risk reduction | Intervention Type: BEHAVIORAL; Name: risk reduction; Assigned to Arm(s): Delayed Intervention, Immediate Intervention

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Improving Coronary Prevention in a County Health System
Brief Summary: To examine whether the Stanford Health Education and Risk Reduction Training (HEAR2T) program , a case management approach, can be effectively used to manage the risk of coronary artery disease.


Options:
A: Arm Label: Novel integrated care concept (NICC); Type: EXPERIMENTAL; Interventions: Other: Novel integrated care concept (NICC) | Arm Label: Standard care; Type: ACTIVE_COMPARATOR; Interventions: Other: Standard care | Intervention Type: OTHER; Name: Novel integrated care concept (NICC); Assigned to Arm(s): Novel integrated care concept (NICC) | Intervention Type: OTHER; Name: Standard care; Assigned to Arm(s): Standard care
B: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Other: Educational Intervention | Arm Label: control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Educational Intervention; Assigned to Arm(s): Intervention
C: Arm Label: Cohort 1; Type: N/A; Interventions: N/A | Arm Label: Cohort 2; Type: N/A; Interventions: N/A | Arm Label: Cohort 3; Type: N/A; Interventions: N/A | Arm Label: Cohort 4; Type: N/A; Interventions: N/A | Arm Label: Cohort 5; Type: N/A; Interventions: N/A
D: Arm Label: Immediate Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: risk reduction | Arm Label: Delayed Intervention; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: risk reduction | Intervention Type: BEHAVIORAL; Name: risk reduction; Assigned to Arm(s): Delayed Intervention, Immediate Intervention

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Improving Coronary Prevention in a County Health System
Brief Summary: To examine whether the Stanford Health Education and Risk Reduction Training (HEAR2T) program , a case management approach, can be effectively used to manage the risk of coronary artery disease.


Options:
A: Arm Label: Algorithm-based care; Type: OTHER; Interventions: Drug: ASA, Atenolol, hydrochlorothiazide, ACE inhibitor, Statin | Arm Label: Health-promotion; Type: OTHER; Interventions: Behavioral: Health Promotion | Intervention Type: DRUG; Name: ASA, Atenolol, hydrochlorothiazide, ACE inhibitor, Statin; Assigned to Arm(s): Algorithm-based care | Intervention Type: BEHAVIORAL; Name: Health Promotion; Assigned to Arm(s): Health-promotion
B: Arm Label: Standard care (SC); Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Standard care | Arm Label: Interventional care (IC); Type: EXPERIMENTAL; Interventions: Behavioral: CAPSYS | Intervention Type: BEHAVIORAL; Name: Standard care; Assigned to Arm(s): Standard care (SC) | Intervention Type: BEHAVIORAL; Name: CAPSYS; Assigned to Arm(s): Interventional care (IC)
C: Arm Label: Interprofessional Team Approach; Type: EXPERIMENTAL; Interventions: Other: Interprofessional Team Approach | Arm Label: Usual Home Care Services; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Interprofessional Team Approach; Assigned to Arm(s): Interprofessional Team Approach
D: Arm Label: Immediate Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: risk reduction | Arm Label: Delayed Intervention; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: risk reduction | Intervention Type: BEHAVIORAL; Name: risk reduction; Assigned to Arm(s): Delayed Intervention, Immediate Intervention

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Improving Coronary Prevention in a County Health System
Brief Summary: To examine whether the Stanford Health Education and Risk Reduction Training (HEAR2T) program , a case management approach, can be effectively used to manage the risk of coronary artery disease.


Options:
A: Arm Label: Health check; Type: EXPERIMENTAL; Interventions: Other: Health check | Arm Label: No invitation; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Health check; Assigned to Arm(s): Health check
B: Arm Label: WHO CVD Risk Assessment package; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: WHO CVD risk assessment package | Arm Label: Health Insurance only; Type: SHAM_COMPARATOR; Interventions: Behavioral: Health Insurance only | Intervention Type: BEHAVIORAL; Name: WHO CVD risk assessment package; Assigned to Arm(s): WHO CVD Risk Assessment package | Intervention Type: BEHAVIORAL; Name: Health Insurance only; Assigned to Arm(s): Health Insurance only
C: Arm Label: Intervention; Type: OTHER; Interventions: Behavioral: Vascular Management Program, Behavioral: Clinical Care Coordinators, Behavioral: Web-based Vascular Tracker for Patient and Physician, Behavioral: Automated Telephone Reminder System | Intervention Type: BEHAVIORAL; Name: Vascular Management Program; Assigned to Arm(s): Intervention | Intervention Type: BEHAVIORAL; Name: Clinical Care Coordinators; Assigned to Arm(s): Intervention | Intervention Type: BEHAVIORAL; Name: Web-based Vascular Tracker for Patient and Physician; Assigned to Arm(s): Intervention | Intervention Type: BEHAVIORAL; Name: Automated Telephone Reminder System; Assigned to Arm(s): Intervention
D: Arm Label: Immediate Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: risk reduction | Arm Label: Delayed Intervention; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: risk reduction | Intervention Type: BEHAVIORAL; Name: risk reduction; Assigned to Arm(s): Delayed Intervention, Immediate Intervention

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Improving Coronary Prevention in a County Health System
Brief Summary: To examine whether the Stanford Health Education and Risk Reduction Training (HEAR2T) program , a case management approach, can be effectively used to manage the risk of coronary artery disease.


Options:
A: Intervention Type: BEHAVIORAL; Name: Exercise and diet - based on DPS and DPP; Assigned to Arm(s): N/A
B: Arm Label: Standard Behavioral Treatment; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Standard Behavioral Treatment | Arm Label: SBT+LOV Group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Standard Behavioral Treatment, Behavioral: SBT+LOV | Intervention Type: BEHAVIORAL; Name: Standard Behavioral Treatment; Assigned to Arm(s): SBT+LOV Group, Standard Behavioral Treatment | Intervention Type: BEHAVIORAL; Name: SBT+LOV; Assigned to Arm(s): SBT+LOV Group
C: Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Self-Management Program; Type: EXPERIMENTAL; Interventions: Behavioral: Self-management program (SM) | Arm Label: Care Management Program; Type: EXPERIMENTAL; Interventions: Behavioral: Care management program (CM) | Intervention Type: BEHAVIORAL; Name: Self-management program (SM); Assigned to Arm(s): Self-Management Program | Intervention Type: BEHAVIORAL; Name: Care management program (CM); Assigned to Arm(s): Care Management Program
D: Arm Label: Immediate Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: risk reduction | Arm Label: Delayed Intervention; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: risk reduction | Intervention Type: BEHAVIORAL; Name: risk reduction; Assigned to Arm(s): Delayed Intervention, Immediate Intervention

Answer: D